GrayMatters for PTSD - GfP A Non-invasive, Adaptive Digital Therapeutic Solution for Post-traumatic Stress Disorder and Other Mental Disorders
- Coordinator
- Graymatters Health Ltd, Israel
- Runs
- 1 September 2022 to 31 May 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190165249
What the project is doing
In the project's own words, from its summary on CORDIS.
Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at 7.5B. Current treatments success is marginal, costly, with severe side-effects. GrayMatters is the first to introduce a non-invasive digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity level using affordable EEG-Neurofeedback device.
Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Graymatters Health Ltd | Haifa | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI